You are in: eMedicine Specialties > Pediatrics: General Medicine > Pulmonology PneumatoceleArticle Last Updated: Apr 2, 2008AUTHOR AND EDITOR INFORMATIONAuthor: Denise Serebrisky, MD, Assistant Professor, Department of Pediatrics, Albert Einstein College of Medicine; Director, Division of Pulmonary Medicine, Lewis M Fraad Department of Pediatrics, Jacobi Medical Center; Director, Jacobi Asthma and Allergy Center for Children Denise Serebrisky is a member of the following medical societies: American Thoracic Society Coauthor(s): Arthur B Atlas, MD, Assistant Clinical Professor, Department of Pediatrics, University of Medicine and Dentistry of New Jersey; Debra Boyer, MD, Fellow, Department of Pediatrics, Division of Pulmonary Medicine, Children's Hospital of Boston Editors: Girish D Sharma, MD, Associate Professor, Department of Pediatrics, Rush University Medical Center, Rush Children's Hospital; Director of Pediatric Pulmonary Section and Rush Cystic Fibrosis Center; Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc; Charles Callahan, DO, Professor, Deputy Chief of Clinical Services, Walter Reed Army Medical Center; Mary E Cataletto, MD, Associate Director, Division of Pediatric Pulmonology, Winthrop University Hospital; Associate Professor, Department of Clinical Pediatrics, State University of New York at Stony Brook; Michael R Bye, MD, Attending Physician, Pediatric Pulmonary Medicine, Columbia University Medical Center; Professor of Clinical Pediatrics, Division of Pulmonary Medicine, Columbia University College of Physicians and Surgeons Author and Editor Disclosure Synonyms and related keywords: pneumatocele, infectious pneumatocele, traumatic pneumatocele, lung cysts, bullae, subpleural emphysema, postinfectious pulmonary cysts, Staphylococcus aureus, pneumonia, Streptococcus pneumoniae, Haemophilus influenzae, Escherichia coli, group A streptococci, Serratia marcescens, Klebsiella pneumoniae, adenovirus, tuberculosis, hydrocarbon ingestion, positive pressure ventilation, ball-valve obstruction, tension pneumatocele, pneumothorax, secondarily infected pneumatocele, hyperimmunoglobulin E syndrome, hyper-IgE syndrome, Buckley-Job syndrome INTRODUCTIONBackgroundPulmonary pneumatoceles are thin-walled, air-filled cysts that develop within the lung parenchyma. They can be single emphysematous lesions but are more often multiple, thin-walled, air-filled, cystlike cavities. Most often, they occur as a sequela to acute pneumonia, commonly caused by Staphylococcus aureus. However, pneumatocele formation also occurs with other agents, including Streptococcus pneumoniae, Haemophilus influenzae, Escherichia coli, group A streptococci, Serratia marcescens, Klebsiella pneumoniae, adenovirus, and tuberculosis. Pneumatoceles are generally observed soon after the development of pneumonia but can be observed on the initial chest radiograph. In most circumstances, pneumatoceles are asymptomatic and do not require surgical intervention.1 Treatment of the underlying pneumonia with antibiotics is the first-line therapy. Close observation in the early stages of the infection and periodic follow-up care until resolution of the pneumatocele is usually adequate treatment. The natural course of a pneumatocele is slow resolution with no further clinical sequelae. Invasive approaches should only be reserved for patients who develop complications. PathophysiologySince the 1950s, multiple theories have been proposed as to the exact mechanism of pneumatocele formation; however, the exact mechanism remains controversial. Carrey suggested that the initial event is inflammation and narrowing of the bronchus, leading to the formation of an endobronchial ball valve.2 Ultimately, this bronchial obstruction leads to distal dilatation of the bronchi and alveoli. In 1951, Conway proposed that a peribronchial abscess forms and subsequently ruptures its contents into the bronchial lumen.3 This also acts similarly to a ball-valve obstruction in the bronchus and leads to distal dilatation. In 1972, Boisset concluded that pneumatoceles are caused by bronchial inflammation that ruptures the bronchiolar walls and causes the formation of "air corridors."4 Air dissects down these corridors to the pleura and forms pneumatoceles, a form of subpleural emphysema. Traumatic pneumatocele has a different pathophysiology from the infectious type,5 developing in a 2-step process. Initially, the lung is compressed by the external force of the trauma, followed by rapid decompression from increased negative intrathoracic pressure. A "bursting lesion" of the lung occurs and leads to pneumatocele formation. FrequencyInternationalIncidence of postinfectious pneumatocele formation ranges from 2-8% of all cases of pneumonia in children.6 However, the frequency can be as high as 85% in staphylococcal pneumonias. Mortality/MorbidityAlthough mortality from the initial pneumonia can be significant, mortality associated with pneumatoceles is quite low. Complete resolution without long-term sequelae is typical; however, rare complications can occur, including the following:
RaceNo specific racial predilection is observed for pneumatocele formation. Because pneumatoceles are usually a complication of pneumonia, the predilection is based on susceptibility for infection. SexNo sex predilection is known. AgeInfants younger than 1 year account for three fourths of the cases of staphylococcal pneumonia. Because pneumatoceles commonly develop as a complication of staphylococcal pneumonia, pneumatoceles are found more frequently in infants and young children. One study reported that 70% of pneumatoceles occurred in children younger than 3 years.7 CLINICALHistoryChildren present with typical features of pneumonia, including cough, fever, and respiratory distress. No clinical findings differentiate pneumonia with or without pneumatocele formation. Physical
Causes
DIFFERENTIALSBronchogenic Cyst Cystic Adenomatoid Malformation Hyperimmunoglobulinemia E (Job) Syndrome Pneumococcal Infections Pneumonia Pulmonary Sequestration Staphylococcus Aureus Infection Tuberculosis
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Oxacillin (Bactocill) |
|---|---|
| Description | A very effective antibiotic for treating S aureus as well as S pneumoniae. |
| Adult Dose | 1-2 g IV/IM q4-6h 500-1000 mg PO q4-6h |
| Pediatric Dose | <7 days, <2000 g: 50 mg/kg/d IV divided q12h <7 days, >2000 g: 75 mg/kg/d IV divided q8h >7 days, <2000 g: 75 mg/kg/d IV divided q8h >7 days, >2000 g: 100mg/kg/d IV divided q6h Infants and children: 150-200 mg/kg/d IV divided q4-6h |
| Contraindications | Documented hypersensitivity |
| Interactions | Oxacillin decreases effects of contraceptives and tetracycline; concomitant administration with disulfiram and probenecid may increase oxacillin levels; effect of anticoagulants increase when large IV doses of oxacillin |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Reported serious adverse effects include thrombocytopenia, neutropenia, hemolytic anemia, and agranulocytosis |
| Drug Name | Ampicillin and sulbactam (Unasyn) |
|---|---|
| Description | Drug combination of beta-lactamase inhibitor with ampicillin. A very effective antibiotic for treating S aureus as well as S pneumoniae. Also effective for many anaerobic infections. |
| Adult Dose | 1.5 (1 g ampicillin + 0.5 g sulbactam) to 3 g (2 g ampicillin + 1 g sulbactam) IV/IM q6h; not to exceed 8 g/d of ampicillin |
| Pediatric Dose | 100-200 mg (based on ampicillin component) per kg/d IV/IM divided q6h |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid and disulfiram elevate ampicillin levels; allopurinol decreases ampicillin effects and has additive effects on ampicillin rash; may decrease effects of PO contraceptives |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Reported serious reactions could include thrombocytopenia, agranulocytosis, anaphylaxis, pseudomembranous colitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, leukopenia, anemia, seizures, and hepatotoxicity; decrease dose with severe renal impairment (ie, CrCl <30 mL/min) |
| Drug Name | Cefuroxime (Zinacef) |
|---|---|
| Description | Very effective antibiotic for treating S aureus and S pneumoniae. |
| Adult Dose | 2.25 g IV/IM q6-8h; not to exceed 9 g/d |
| Pediatric Dose | Neonates: 20-40 mg/kg/d IV/IM divided q12h Infants and children: 50-100 mg/kg/d IV/IM divided q6-8h |
| Contraindications | Documented hypersensitivity |
| Interactions | A false-positive reaction for glucose in the urine can occur with copper reduction tests (ie, Clinitest tablets); false-negative results may occur with ferricyanide test (use glucose oxidase or hexokinase methods); disulfiramlike reactions may occur when alcohol is consumed within 72 h after taking cefuroxime; may increase hypoprothrombinemic effects of anticoagulants; may increase nephrotoxicity in patients receiving potent diuretics such as loop diuretics; coadministration with aminoglycosides increases nephrotoxic potential |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Reported serious reactions include thrombocytopenia, agranulocytosis, anaphylaxis, pseudomembranous colitis, interstitial nephritis, seizures, hemolytic anemia, and neutropenia; reduce dosage by one half if CrCl is 10-30 mL/min and by three fourths if CrCl <10 mL/min (high doses may cause CNS toxicity); bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy |
| Drug Name | Vancomycin (Lyphocin, Vancocin, Vancoled) |
|---|---|
| Description | Very effective antibiotic for treating methicillin-resistant S aureus as well as for treating penicillin-resistant S pneumoniae. To avoid toxicity, current recommendation is to assay vancomycin trough levels before fourth dose. Use CrCl to adjust dose in patients with renal impairment. |
| Adult Dose | 500 mg IV q6h |
| Pediatric Dose | <7 days, <1200 g: 15 mg/kg/dose IV q24h <7 days, 1200-2000 g: 15 mg/kg/dose IV q12-18h <7 days, >2000 g: 30 mg/kg/d IV divided q12h >7 days, <1200 g: 15 mg/kg/dose IV q24h >7 days, 1200-2000 g: 15 mg/kg/dose IV q8-12h >7 days, >2000 g: 45 mg/kg/d IV divided q8h Infants and children: 40-60 mg/kg/d IV divided q8h |
| Contraindications | Documented hypersensitivity |
| Interactions | Erythema, histaminelike flushing, and anaphylactic reactions may occur when administered with anesthetic agents; concurrent administration with aminoglycosides may increase the risk of nephrotoxicity above that with aminoglycoside monotherapy; effects in neuromuscular blockade may be enhanced when coadministered with nondepolarizing muscle relaxants |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Reported serious reactions include neutropenia, anaphylaxis, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis, nephrotoxicity, and ototoxicity; rapid infusion has been associated with red man syndrome, which can be mistaken for acute allergic reaction |
| Drug Name | Clindamycin (Cleocin) |
|---|---|
| Description | Very effective antibiotic for treating S aureus as well as S pneumoniae. Lincosamide for treatment of serious skin and soft tissue staphylococcal infections. Also effective against aerobic and anaerobic streptococci (except enterococci). Inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. |
| Adult Dose | 300-900 mg IV/IM q6-12h; not to exceed 600 mg/dose IM or 4800 mg/d IV 150-450 mg PO qid |
| Pediatric Dose | Infants and children: 15-40 mg/kg/d IV/IM divided q6-8h 10-25 mg/kg/d PO divided q6-8h |
| Contraindications | Documented hypersensitivity; regional enteritis; ulcerative colitis; hepatic impairment; antibiotic-associated colitis |
| Interactions | Increases duration of neuromuscular blockade induced by tubocurarine and pancuronium; erythromycin may antagonize effects of clindamycin; antidiarrheals may delay absorption of clindamycin |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Reported serious reactions include pseudomembranous colitis, diarrhea, thrombocytopenia, anaphylaxis, Stevens-Johnson syndrome, granulocytopenia, and esophagitis |
| Drug Name | Ciprofloxacin (Cipro) |
|---|---|
| Description | Very effective antibiotic for treating S aureus as well as S pneumoniae. A fluoroquinolone with activity against Pseudomonas, streptococci, MRSA, S epidermidis, and most gram-negative organisms but no activity against anaerobes. Inhibits bacterial DNA synthesis and consequently growth. |
| Adult Dose | 250-750 mg PO q12h 200-400 mg IV q12h |
| Pediatric Dose | 20-30 mg/kg/d PO divided q12h; not to exceed 1.5 g/d 10-20 mg/kg/d IV divided q12h; not to exceed 800 mg/d |
| Contraindications | Documented hypersensitivity; not approved for use in children <18 y; pregnancy; caution with impaired renal or liver function |
| Interactions | Antacids, iron salts, and zinc salts may reduce serum levels; administer antacids 2-4 h before or after taking fluoroquinolones; cimetidine may interfere with metabolism of fluoroquinolones; ciprofloxacin reduces therapeutic effects of phenytoin; probenecid may increase ciprofloxacin serum concentrations; may increase toxicity of theophylline, caffeine, cyclosporine, and digoxin (monitor digoxin levels); may increase effects of anticoagulants (monitor PT) |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Reported serious reactions include hepatotoxicity, seizures, anaphylaxis, Achilles tendon rupture, and pseudomembranous colitis |
Although most pneumatoceles resolve without sequelae, recognition of the following potential complications may prevent an unexpected poor outcome:
| Media file 1: Pneumonia with multiple pneumatoceles. | |
![]() | View Full Size Image | Media type: Radiograph |
| Media file 2: Pneumonia with pneumatocele (lateral). | |
![]() | View Full Size Image | Media type: Radiograph |
| Media file 3: Resolving pneumatocele. | |
![]() | View Full Size Image | Media type: Radiograph |
| Media file 4: Chest CT scan of pneumonia with pneumatocele. | |
![]() | View Full Size Image | Media type: CT |
Article Last Updated: Apr 2, 2008